K
Pasithea Therapeutics Corp.
KTTACIK 0001841330NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-20.43M
Total Assets
$60.24M
Equity
$55.22M
Shares Out
33.41M
Op. Cash Flow
$-15.21M
Business
Pasithea Therapeutics is a clinical-stage biotechnology company developing innovative treatments for RASopathies, MAPK pathway-driven tumors, and CNS disorders. Its lead product candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor in Phase 1 clinical trials for advanced cancers and neurofibromatosis type 1 plexiform neurofibromas. The company also has an early-stage discovery program, PAS-001, targeting C4A for schizophrenia. Pasithea operates globally with clinical trial sites across the U.S., Eastern Europe, Australia, and South Korea.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative | 13 | 7 | — | — | — | |
| Research and development | 8 | 7 | 8 | 3 | — | |
| Loss from operations | −21 | −14 | −16 | −13 | −5 | |
| Change in fair value of warrant liabilities | 115,301 | −77,806 | 56,245 | 2 | 2 | |
| Realized foreign currency translation loss from dissolution of subsidiaries | −7,171 | — | — | — | — | |
| Foreign currency gain | 30,376 | — | — | — | — | |
| Other income | 380,532 | — | — | — | — | |
| Change in fair value of derivative warrant liability | −416,619 | — | — | — | — | |
| Interest and dividends, net | 327,193 | 423,184 | 415,368 | — | — | |
| Other income, net | 429,612 | 345,378 | 471,613 | — | 2 | |
| Loss before income taxes | −20 | −14 | −16 | −12 | −2 | |
| Provision for income taxes | — | — | — | — | — | |
| Net loss | −20 | −14 | −16 | −14 | −2 | |
| Weighted-average common shares outstanding, basic (in Shares) | 7 | 1 | 1 | 1 | 10 | |
| Weighted-average common shares outstanding, diluted (in Shares) | 7 | 1 | 1 | 1 | 10 | |
| Basic loss per share (in Dollars per share) | −2.91 | −12.69 | — | −0.55 | −0.21 | |
| Diluted loss per share (in Dollars per share) | −2.91 | −12.69 | — | −0.53 | −0.21 | |
| Foreign currency translation | 18,766 | −2,519 | −3,991 | 9,900 | −10,561 | |
| Comprehensive loss | −20 | −14 | −16 | −14 | −2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 55 | 7 | 16 | 33 | 53 | |
| Restricted cash | 100,866 | — | — | — | — | |
| Prepaid expenses | 811,456 | 302,641 | 215,895 | 562,375 | 333,751 | |
| Other current assets | 387,823 | 142,945 | 104,707 | 262,992 | — | |
| Total current assets | 56 | 7 | 17 | 34 | 53 | |
| Property and equipment, net | — | 122,343 | 141,208 | 125,197 | 20,124 | |
| Intangibles, net | 4 | 7 | — | — | — | |
| Goodwill | — | 1 | 1 | 1 | — | |
| Total assets | 60 | 16 | 26 | 45 | 53 | |
| Accounts payable and accrued liabilities | 1 | 1 | 3 | 1 | 447,280 | |
| Warrant liabilities Placement Agent Warrants | 4 | — | — | — | — | |
| Total current liabilities | 5 | 1 | 3 | 2 | 447,280 | |
| Warrant liabilities | 46,871 | 162,172 | 84,366 | 140,611 | — | |
| Total non-current liabilities | 46,871 | 162,172 | 84,366 | 804,207 | 1 | |
| Total liabilities | 5 | 1 | 3 | 3 | 2 | |
| Preferred stock, par value $0.0001 per share, 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 23,091,062 shares and 1,394,263 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 2,309 | 139 | 104 | 130 | 17,684 | |
| Additional paid-in capital | 125 | 64 | 59 | 62 | 54 | |
| Accumulated other comprehensive income (loss) | 18,766 | −7,171 | −4,652 | −661 | −10,561 | |
| Accumulated deficit | −70 | −50 | −35 | −19 | −2 | |
| Total stockholders equity | 55 | 15 | 23 | 42 | 51 | |
| Total liabilities and stockholders equity | 60 | 16 | 26 | 45 | 53 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 32,000 | 19,000 | 18,290 | 5,094 | 1,379 | |
| Amortization expense | 630,164 | 630,164 | 630,164 | — | — | |
| Stock-based compensation | 297,467 | 773,693 | 592,269 | 835,064 | 471,250 | |
| Impairment expense | 4 | — | — | — | — | |
| Realized foreign currency translation loss from dissolution of subsidiaries | 7,171 | — | — | — | — | |
| Loss on asset disposal | 103,322 | — | — | — | — | |
| Prepaid expenses | −60,536 | −86,746 | 346,480 | −181,374 | −329,443 | |
| Other current assets | −269,278 | 2,262 | — | — | — | |
| Accounts payable and accrued liabilities | 11,233 | −1 | 1 | 745,759 | 440,677 | |
| Lease liabilities | — | −2,409 | −1,547 | 543,956 | 440,677 | |
| Net cash used in operating activities | −15 | −14 | — | −15 | −3 | |
| Proceeds from the sale of equipment | 11,000 | — | 109,500 | — | — | |
| Net cash provided by investing activities | 11,000 | — | — | −2 | −21,503 | |
| Payments on financed director and officer insurance | −448,279 | — | — | — | — | |
| Proceeds from issuance of common stock under ATM agreement, net of fees and offering costs | 2 | — | — | — | 1 | |
| Proceeds from issuance of common stock from the exercise of pre-funded warrants, net | 871 | 349 | — | — | — | |
| Proceeds from May 2025 public offering of common stock, net | 4 | — | — | — | 5 | |
| Proceeds from December 2025 public offering of common stock, net | 55 | — | — | — | — | |
| Issuance of common stock from the exercise of warrants, net | 2 | — | — | — | 7 | |
| Proceeds from September 2024 offering of pre-funded and common warrants, net | — | 5 | — | — | — | |
| Net cash provided by financing activities | 64 | 5 | — | −3 | 56 | |
| Effect of foreign currency translation on cash | 18,766 | −2,519 | −3,991 | — | — | |
| NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | 48 | −9 | −17 | −20 | 53 | |
| Cash paid for interest | 13,212 | — | — | — | — | |
| Cash paid for taxes | — | — | — | — | — | |
| Dividend - warrant modification | — | −359,656 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Pasithea Therapeutics Corp.'s CIK number?
Pasithea Therapeutics Corp.'s SEC CIK number is 0001841330 (1841330). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pasithea Therapeutics Corp.'s SEC filings?
All of Pasithea Therapeutics Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.